ENGN US Equity
enGene Therapeutics Inc.Health Care · Biological Products, (No Diagnostic Substances) · CIK 1980845 · FY ends Oct 31$1.78
+0.01 (+0.56%)
USD · as of 2026-08-21 · marketstack
Short interest· FINRA consolidated · settlement 2026-07-31
6 settlement cycles| Shares short | 1.7M |
| % of shares out | 2.6% |
| Days to cover | 2.5 |
| Δ vs 2026-07-15 | +5.7% |
bars = shares short · line = days to cover (own scale)
| Settlement | Shares short | Δ vs prior | Avg daily volume | Days to cover |
|---|
| 2026-07-31 | 1,733,296 | +5.7% | 680,561 | 2.5 |
| 2026-07-15 | 1,640,215 | +43.7% | 1,255,969 | 1.3 |
| 2026-06-30 | 1,141,694 | -17.9% | 1,116,776 | 1.0 |
| 2026-06-15 | 1,390,080 | -14.3% | 859,253 | 1.6 |
| 2026-05-29 | 1,622,269 | +11.5% | 1,466,173 | 1.1 |
| 2026-05-15 | 1,455,269 | -27.4% | 5,752,614 | 1.0 |
FINRA Rule 4560 · twice monthly, published ~a week later.
Output of a disclosed model — assumptions may be wrong. Research, not investment advice. See the Disclaimer.
